Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer, raised $155M in Series B funding.
The round was co-led by Redmile Group and Bain Capital Life Sciences with participation from RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, funds managed by Tekla Capital Management, funds and accounts managed by BlackRock, Mass General Brigham Ventures, Eurofarma, and Soleus Capital.
The company intends to use the funds to complete a Phase 2/3 registrational clinical trial evaluating ABC008, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myositis (IBM), and a Phase 1/2 clinical trial of ABC008 in T cell large granular lymphocytic leukemia (T-LGLL), as well as to initiate a Phase 1/2 clinical trial in T and NK cell lymphomas.
Led by CEO Alex Martin, and Chief Medical Officer H. Jeffrey Wilkins, M.D., Abcuro is a clinical stage biotechnology company developing immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company is conducting two clinical trials in rare diseases: a Phase 2/3 registrational trial evaluating ABC008 in inclusion body myositis (IBM,) and a Phase 1/2 trial evaluating ABC008 in T cell large granular lymphocytic leukemia.
FinSMEs
18/08/2023